Adults with atopic dermatitis who start a Janus kinase inhibitor are more than twice as likely to develop acne within six months as those treated with Th2 cytokine inhibitors, according to a new study.

Findings from the large real-world US-based study put numbers on a risk long suggested by clinical trials and reinforced acne as a class effect clinicians should be prepared for, educate patients about and manage early.

The results were published as a research letter in JAMA Dermatology .

“In this cohort study, we found an increased risk of acne, but not folliculitis or rosacea, among patients starting a JAK inhibitor for AD treatment,” the researchers wrote.

“Findings are representative of US clinical practice but included no data on high-dose JAK inhibitor use or AD severity.

“In conclusion, physicians and patients should consider that starting low-dose JAK inhibitors may increase the risk of acne.”

Using the multiyear ADVANCES sequential monitoring system, investigators analysed longitudinal commercial claims data claims from January 2017 to May 2024.